LifeVantage Reports Full Clinical Results Including Average of 140% Increase in GLP-1 with the MindBody GLP-1 System™Ω
LifeVantage (LFVN) announced results from a human clinical trial of their MindBody GLP-1 System™, showing a 140% average increase in GLP-1 levels and significant weight loss outcomes. The 12-week study involved 60 subjects with BMI≥25, divided into three groups. Key findings include: 92% of participants lost weight (average 11 pounds), 92% reduced total body fat, and 71% decreased visceral fat. Notably, participants reported improved relationships with food, with 95% experiencing decreased sugar cravings and 96% reducing portion sizes. The system uses natural ingredients to activate GLP-1 production without reported side effects.
LifeVantage (LFVN) ha annunciato i risultati di uno studio clinico umano del loro MindBody GLP-1 System™, mostrando un aumento medio del 140% nei livelli di GLP-1 e risultati significativi nella perdita di peso. Lo studio di 12 settimane ha coinvolto 60 soggetti con BMI≥25, divisi in tre gruppi. Tra i risultati chiave, il 92% dei partecipanti ha perso peso (media di 11 libbre), il 92% ha ridotto la massa grassa totale e il 71% ha diminuito il grasso viscerale. È importante notare che i partecipanti hanno segnalato un miglioramento nelle relazioni con il cibo, con il 95% che ha avvertito una diminuzione delle voglie di zucchero e il 96% che ha ridotto le dimensioni delle porzioni. Il sistema utilizza ingredienti naturali per attivare la produzione di GLP-1 senza effetti collaterali riportati.
LifeVantage (LFVN) anunció los resultados de un ensayo clínico humano de su MindBody GLP-1 System™, mostrando un aumento promedio del 140% en los niveles de GLP-1 y resultados significativos en la pérdida de peso. El estudio de 12 semanas involucró a 60 sujetos con BMI≥25, divididos en tres grupos. Los hallazgos clave incluyen: el 92% de los participantes perdió peso (promedio de 11 libras), el 92% redujo la grasa corporal total y el 71% disminuyó la grasa visceral. Cabe destacar que los participantes informaron una mejora en sus relaciones con la comida, con el 95% experimentando menos antojos de azúcar y el 96% reduciendo el tamaño de las porciones. El sistema utiliza ingredientes naturales para activar la producción de GLP-1 sin efectos secundarios reportados.
라이프반테이지 (LFVN)는 마인드바디 GLP-1 시스템™의 인간 임상 시험 결과를 발표하며 GLP-1 수치가 평균 140% 증가하고 상당한 체중 감소 결과를 보였다고 밝혔습니다. 12주 간의 연구에는 BMI≥25인 60명의 대상자가 참여하였으며, 세 그룹으로 나누어 진행되었습니다. 주요 발견은 92%의 참가자가 체중을 감량했으며(평균 11파운드) 92%가 총 체지방을 줄였고, 71%가 내장 지방을 감소시켰다는 점입니다. 특히, 참가자들은 음식과의 관계가 개선되었다고 보고했으며, 95%가 설탕에 대한 갈망이 줄어들고 96%가 음식의 양을 줄였다고 합니다. 이 시스템은 보고된 부작용 없이 GLP-1 생성을 활성화하기 위해 천연 성분을 사용합니다.
LifeVantage (LFVN) a annoncé les résultats d'un essai clinique humain de leur MindBody GLP-1 System™, montrant une augmentation moyenne de 140% des niveaux de GLP-1 et des résultats significatifs en matière de perte de poids. L'étude de 12 semaines a impliqué 60 sujets avec un IMC≥25, répartis en trois groupes. Parmi les résultats clés, 92% des participants ont perdu du poids (en moyenne 11 livres), 92% ont réduit leur masse grasse totale et 71% ont diminué leur graisse viscérale. Notamment, les participants ont rapporté une amélioration de leurs relations avec la nourriture, avec 95% ressentant une diminution des envies de sucre et 96% réduisant les tailles des portions. Le système utilise des ingrédients naturels pour activer la production de GLP-1 sans effets secondaires signalés.
LifeVantage (LFVN) hat die Ergebnisse einer menschlichen klinischen Studie zu ihrem MindBody GLP-1 System™ bekanntgegeben, die einen durchschnittlichen Anstieg der GLP-1-Werte um 140% und signifikante Ergebnisse beim Gewichtsverlust zeigt. Die 12-wöchige Studie umfasste 60 Probanden mit einem BMI≥25, die in drei Gruppen aufgeteilt wurden. Zu den wichtigsten Ergebnissen gehören: 92% der Teilnehmer verloren Gewicht (durchschnittlich 11 Pfund), 92% reduzierten das Körperfett insgesamt und 71% verringerten das viszerale Fett. Bemerkenswert ist, dass die Teilnehmer von einer Verbesserung ihres Verhältnisses zu Nahrungsmitteln berichteten, wobei 95% weniger Zuckergelüste verspürten und 96% die Portionsgrößen reduzierten. Das System nutzt natürliche Inhaltsstoffe, um die Produktion von GLP-1 zu aktivieren, ohne berichtete Nebenwirkungen.
- Clinical trial showed 140% average increase in GLP-1 levels
- 92% of participants achieved weight loss (average 11 pounds)
- 92% of subjects showed reduction in total body fat (up to 5.5%)
- 71% experienced visceral fat reduction (up to 27%)
- No side effects reported in clinical trials
- 100% of weight-loss subjects maintained or increased muscle percentage
- None.
Insights
The clinical trial results for LifeVantage's MindBody GLP-1 System demonstrate significant potential in the growing GLP-1 market. The 140% average increase in GLP-1 levels and 92% success rate in weight loss among participants are particularly noteworthy. The study's design with 60 subjects and three distinct groups provides credible data points.
Key differentiators include the natural approach to GLP-1 activation and the absence of common side effects that plague pharmaceutical GLP-1 alternatives. The dual mechanism of direct L-cell activation and gut microbiome optimization represents a novel approach. The maintenance or increase in muscle mass in weight-loss subjects addresses a common concern with traditional weight loss methods.
The behavioral changes reported by participants suggest sustainable long-term outcomes, with 85-95% reporting improved relationships with food and reduced cravings. The additional in vitro data showing 38% reduction in DPP-4 gene expression and 53% increase in GLP1R expression provides mechanistic support for the clinical findings.
This breakthrough positions LifeVantage strategically in the rapidly expanding GLP-1 market, currently dominated by pharmaceutical companies. With a market cap of
The direct-to-consumer business model through consultants provides a unique distribution advantage, potentially enabling faster market penetration with lower marketing costs. The comprehensive clinical validation strengthens the product's competitive position and could drive both consultant recruitment and consumer adoption, potentially accelerating revenue growth in coming quarters.
Natural Approach to GLP-1 Activation Proves Effective Without Common Side Effects*
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leader in health and wellness solutions designed to activate optimal health processes at the cellular level, today announced groundbreaking results from a human clinical trial performed on the new MindBody GLP-1 System™. Results from the trial included a
Production of GLP-1 (glucagon-like peptide-1) in the body declines due to age, poor diet, stress, or other lifestyle factors. The decline can cause cravings, false hunger, and weight gain. The MindBody GLP-1 System uses naturally-sourced ingredients to directly activate natural GLP-1 production in L-cells, supporting that activation indirectly by optimizing the gut microbiome to create short-chain fatty acids and fuel production. Ω*
The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, the MindBody GLP-1 System could holistically and sustainably increase GLP-1 hormone levels in overweight adults, without unwanted side effects.*
The study was conducted by independent researchers at Lighthouse Research. Sixty subjects ages 31–78 years with a BMI≥25 were randomized into three groups: a control group with no product use, a group using the MindBody GLP-1 System without diet and exercise guidelines, and a group using the MindBody GLP-1 System with diet and exercise guidelines.
Subjects were evaluated every 4 weeks. Visits included anthropometric and biometric measurements, before and after photographs, food behavior questionnaires, and blood work for GLP-1 analysis.
Key 12-week findings from the human trial include:
140% increase of GLP-1 on average Ω92% of participants lost weight, with an average of 11 pounds ‡92% saw a reduction in total body fat, with up to a5.5% decrease ‡71% experienced a reduction in visceral fat, with up to a27% decrease ‡100% of subjects who lost weight (92% of total subjects) maintained or saw an increase in muscle %, with up to a2.7% increase ‡- No side effects were reported, including gastrointestinal issues*
In addition to these physical results, participants reported notable changes in their relationship with food:
85% agreed their food cravings decreased*95% agreed their sugar cravings decreased*96% agreed their portion sizes at each meal decreased*85% agreed they now eat for health, not emotional reasons*82% felt more in control of their relationship with food*
“These human clinical results validate our natural approach to GLP-1 activation, setting us apart from other products on the market,” said Lisa Barnes, Vice President of Research and Development at LifeVantage. “We have shown that the MindBody GLP-1 System activates GLP-1 by a phenomenal
The clinical trial builds on successful in vitro research, which found that the MindBody GLP-1 System significantly increased GLP-1 production in L-cells by activating key genes. The in vitro study also revealed a
"LifeVantage is committed to leading the future of health and wellness by delivering innovative, natural solutions that truly make a difference," said Steve Fife, CEO of LifeVantage. "The outstanding success of the MindBody GLP-1 System trial demonstrates the transformative power of our activation approach, proving natural GLP-1 activation can not only help people manage their weight but also significantly enhance their overall health. Our Consultants are able to change lives and build a thriving business with this science and innovation.”*
To learn more about the clinical trial findings or explore how the MindBody GLP-1 System™ can fit into your wellness routine, visit www.lifevantage.com.
For more information about LifeVantage and its innovative MindBody GLP-1 System™ visit: https://www.lifevantage.com/us-en.
About LifeVantage Corporation
LifeVantage Corporation® (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System™, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own sales business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*
Public Relations Contact:
Jennifer Rumble, CerconeBrownCompany
(704) 923-6378
jrumble@cerconebrown.com
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
§Results based on a cell culture study on active ingredient blends in the MindBody GLP-1 System™.
‡Results may vary. Typical weight loss using this product in a 12-week weight management program is 1–2 pounds per week. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program.
Ω Results based on a randomized 12-week human clinical study.
FAQ
What were the main results of LifeVantage's (LFVN) MindBody GLP-1 System clinical trial?
How many participants were in the LFVN MindBody GLP-1 System clinical trial?
What percentage of LFVN MindBody GLP-1 System users reported reduced food cravings?
